Vascepa, a prescription medicine used to reduce the risk of cardiovascular events in certain patients, is available in Europe under the brand name Vazkepa [3]. Amarin, the pharmaceutical company that produces Vascepa, launched the drug in Europe in March 2021 [2]. Vazkepa is approved by the European Medicines Agency (EMA) for use in adults who have high levels of triglycerides, a type of fat in the blood that can increase the risk of heart disease [3]. The EMA's approval of Vazkepa was based on clinical trials that showed the drug reduced the risk of cardiovascular events in patients with high triglyceride levels [3]. Prior to the launch of Vazkepa, Vascepa was not available in Europe [2]. Therefore, it can be concluded that Vascepa is now available in Europe under the brand name Vazkepa.

Sources:
[2] https://www.fiercepharma.com/marketing/amarin-launches-vascepa-all-important-europe-as-blockbuster-to-be-heart-drug-slowly
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa